Daily Arxiv

This is a page that curates AI-related papers published worldwide.
All content here is summarized using Google Gemini and operated on a non-profit basis.
Copyright for each paper belongs to the authors and their institutions; please make sure to credit the source when sharing.

Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy

Created by
  • Haebom

Author

Junwei Su, Cheng Xin, Ao Shang, Shan Wu, Zhenzhen Xie, Ruogu Xiong, Xiaoyu Xu, Cheng Zhang, Guang Chen, Yau-Tuen Chan, Guoyi Tang, Ning Wang, Yong Xu, Yibin Feng

Outline

This paper provides a systematic review of how artificial intelligence (AI), especially machine learning (ML), can be applied across the drug discovery pipeline. To address the complexity, high cost, long time, and high failure rate of existing drug discovery methods, a comprehensive understanding of how to effectively integrate AI/ML into the entire process is needed. This paper analyzes the application of AI/ML step by step, considering the interdependencies between key steps such as target identification, hit screening, and lead optimization, and highlights methodological advancements and their impact at each step. In-depth case studies focusing on hyperuricemia, gouty arthritis, and hyperuricemic nephropathy demonstrate practical impacts, and suggest challenges and future research directions for AI/ML in drug discovery. This provides essential guidance for researchers seeking to overcome existing bottlenecks and accelerate drug discovery by leveraging AI/ML.

Takeaways, Limitations

Takeaways:
Provides a comprehensive understanding of how to integrate AI/ML into the entire drug development process
A detailed analysis of the methodological advancements and impact of AI/ML at each stage of drug development.
Presenting the practical effectiveness of AI/ML through real case studies focusing on diseases related to hyperuricemia
Presenting future research directions for AI/ML-based new drug development
Suggesting the possibility of resolving and accelerating the bottleneck of existing new drug development
Limitations:
Focused on case studies of specific diseases (diseases related to hyperuricemia), so generalization to other diseases may be limited
The pace of AI/ML technology development is fast, so there is a possibility that new technologies or approaches will emerge after the paper is published.
There may be a lack of discussion on the ethical and social aspects of AI/ML applications.
👍